Get the Stockscreener App
48.96
1.63%
-0.81
After Hours:
49.93
0.97
+1.98%
Avidity Biosciences Inc stock is traded at $48.96, with a volume of 1.26M.
It is down -1.63% in the last 24 hours and up +9.43% over the past month.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
See More
Previous Close:
$49.77
Open:
$50.48
24h Volume:
1.26M
Relative Volume:
0.40
Market Cap:
$7.14B
Revenue:
$10.73M
Net Income/Loss:
$-455.74M
P/E Ratio:
-13.76
EPS:
-3.5569
Net Cash Flow:
$-502.70M
1W Performance:
+6.02%
1M Performance:
+9.43%
6M Performance:
+91.40%
1Y Performance:
+5.06%
1-Day Range:
$48.61
$50.86
1-Week Range:
$45.47
$52.17
52-Week Range:
$21.51
$56.00
Avidity Biosciences Inc Stock (RNA) Company Profile
Name
Avidity Biosciences Inc
Sector
Industry
Phone
858-401-7900
Address
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare RNA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
48.96 | 7.26B | 10.73M | -455.74M | -502.70M | -3.5569 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Avidity Biosciences Inc Stock (RNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Initiated | Roth Capital | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Jun-24-25 | Initiated | Bernstein | Outperform |
| Jun-17-25 | Initiated | Wolfe Research | Outperform |
| Jun-11-25 | Initiated | Raymond James | Strong Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-20-24 | Initiated | H.C. Wainwright | Buy |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-24 | Initiated | Goldman | Buy |
| Aug-28-24 | Initiated | Barclays | Overweight |
| May-03-24 | Initiated | BofA Securities | Buy |
| Mar-14-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-22-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Mar-31-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Strong Buy |
| Sep-07-21 | Initiated | Evercore ISI | Outperform |
| Jun-17-21 | Initiated | Needham | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | Cowen | Outperform |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| Jul-07-20 | Initiated | SVB Leerink | Outperform |
| Jul-07-20 | Initiated | Wells Fargo | Overweight |
View All
Avidity Biosciences Inc Stock (RNA) Latest News
Will a bounce in Avidity Biosciences Inc. offer an exitJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
What momentum shifts mean for Avidity Biosciences Inc.July 2025 Review & Entry Point Confirmation Alerts - newser.com
Avidity reports positive pre-BLA meeting on Duchenne muscular dystrophy asset del-zota - Seeking Alpha
How Avidity Biosciences Inc. stock performs in weak economy2025 Short Interest & Daily Volume Surge Trade Alerts - newser.com
Using R and stats models for Avidity Biosciences Inc. forecastingTrade Ideas & AI Enhanced Trading Signals - newser.com
Forecasting Avidity Biosciences Inc. price range with options dataJuly 2025 Fed Impact & Advanced Technical Signal Analysis - newser.com
Sector ETF performance correlation with Avidity Biosciences Inc.Market Performance Report & Verified Momentum Watchlists - newser.com
Avidity rises on plans to submit muscle wasting drug application to US FDA - TradingView
Avidity Biosciences Completes FDA Pre-BLA Meeting for Del-Zota, Targets 2026 Submission - MarketScreener
Avidity Biosciences delays DMD drug submission to Q1 2026 - Investing.com India
Can Avidity Biosciences Inc. stock beat market expectations this quarterMarket Growth Review & Verified Technical Trade Signals - newser.com
Q1 2026 BLA Planned: Avidity's Breakthrough Therapy del‑zota Receives Positive FDA Pre‑BLA Guidance - Stock Titan
How Avidity Biosciences Inc. stock compares to growth peersQuarterly Profit Review & Safe Entry Trade Reports - newser.com
What Makes Avidity Biosciences (RNA) an Investment Choice? - Yahoo Finance
Avidity Biosciences, Inc. (RNA) Stock Analysis: Exploring a 36.85% Potential Upside in Innovative RNA Therapeutics - DirectorsTalk Interviews
Chart based exit strategy for Avidity Biosciences Inc.Market Growth Review & Low Risk Entry Point Tips - newser.com
Avidity Biosciences Inc. stock daily chart insightsGap Down & Weekly Top Performers Watchlists - newser.com
Can Avidity Biosciences Inc. stock hit record highs againPortfolio Value Report & Low Risk High Win Rate Stock Picks - newser.com
Avidity Biosciences (NASDAQ:RNA) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Ranking Avidity Biosciences Inc. among high performing stocks via toolsWeekly Stock Recap & Weekly High Momentum Picks - newser.com
Is Avidity Biosciences Inc a good long term investmentMid Cap Growth Trends & Low Entry Capital Stocks - earlytimes.in
What drives Ball Corporation stock priceBlue Chip Stock Analysis & High Return Trading Portfolio - earlytimes.in
Avidity Biosciences’ Phase 2 Study on AOC 1001: A Potential Game-Changer for DM1 Treatment - TipRanks
Avidity Biosciences (NASDAQ:RNA) Insider Eric Mosbrooker Sells 6,562 Shares - MarketBeat
Avidity Biosciences to Present Data from EXPLORE44® Clinical Development Program of Del-Zota in DMD44 at 30th Annual Congress of the World Muscle Society - Sahm
Avidity Biosciences (RNA): Assessing Valuation Following Recent Positive Share Price Momentum - Yahoo Finance
Avidity Poised For Commercialization Transformation - San Diego Business Journal
Quantitative breakdown of Avidity Biosciences Inc. recent move2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
Avidity Biosciences Inc. stock trendline breakdownPortfolio Value Report & Free Weekly Watchlist of Top Performers - newser.com
Avidity Biosciences Inc Stock Analysis and ForecastStock Price Targets & 5 Stocks Every Investor Should Own - earlytimes.in
Combining machine learning predictions for Avidity Biosciences Inc.Buy Signal & Fast Moving Stock Watchlists - newser.com
Relative strength of Avidity Biosciences Inc. in sector analysisJuly 2025 Action & High Accuracy Trade Signal Alerts - newser.com
Avidity Biosciences, Inc. (NASDAQ:RNA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Avidity Biosciences Stock Price, Quotes and Forecasts | NASDAQ:RNA - Benzinga
BofA Securities Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $65 - 富途牛牛
Can Avidity Biosciences Inc. hit a new high this monthEarnings Summary Report & Weekly Market Pulse Updates - newser.com
Real time scanner hits for Avidity Biosciences Inc. explainedBull Run & Technical Entry and Exit Alerts - newser.com
Is Avidity Biosciences Inc. building a consolidation baseJuly 2025 Catalysts & Weekly Breakout Stock Alerts - newser.com
Avidity Biosciences Prices $600 Million Upsized Public Offering of Common Stock - Global Legal Chronicle
Avidity Biosciences Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Avidity Biosciences Inc Stock (RNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Avidity Biosciences Inc Stock (RNA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mosbrooker Eric | Chief Commercial Officer |
Oct 03 '25 |
Sale |
45.38 |
6,562 |
297,771 |
55,000 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Option Exercise |
10.16 |
2,208 |
22,433 |
41,075 |
| Hughes Steven George | Chief Medical Officer |
Sep 22 '25 |
Sale |
40.58 |
2,208 |
89,601 |
38,867 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Option Exercise |
22.34 |
15,000 |
335,100 |
112,130 |
| McCarthy Teresa | Chief Human Resources Officer |
Sep 15 '25 |
Sale |
41.41 |
15,000 |
621,142 |
97,130 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Option Exercise |
6.57 |
1,542 |
10,131 |
40,409 |
| Hughes Steven George | Chief Medical Officer |
Sep 15 '25 |
Sale |
45.41 |
1,542 |
70,022 |
38,867 |
| Flanagan W. Michael | Chief Scientific Officer |
Sep 11 '25 |
Option Exercise |
14.22 |
20,000 |
284,400 |
100,195 |
| Flanagan W. Michael | Chief Scientific Officer |
Sep 11 '25 |
Sale |
38.94 |
20,000 |
778,702 |
80,195 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):